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Abstract
Treatment options for Epstein-Barr virus (EBV)-associated Burkitt lymphoma in Africa are
limited because of chemotherapy-associated toxicity. Since other EBV-associated diseases
respond to antiviral agents, we investigated adding an antiviral agent, valacyclovir, to the current
chemotherapy regimen in Malawi. In this phase I safety study, we showed that cyclophosphamide
combined with valacyclovir was safe. Phase II efficacy trials should now be undertaken.
Background—Nucleoside analogues, including acyclovir, ganciclovir, and their precursors,
have shown some efficacy against several Epstein-Barr virus (EBV)-associated diseases, including
active EBV infection and posttransplantation lymphoproliferative disorder (PTLD). They have
also been proposed as a possible treatment for EBV-associated malignancies, including endemic
Burkitt lymphoma. The safety of nucleoside analogues in combination with chemotherapy in the
developing world has not been studied and is necessary before any large scale efficacy trials are
conducted.
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Patients and Methods—Children 3–15 years old meeting inclusion criteria were assigned to a
3+3 dose escalation trial of combination valacyclovir (15 and 30 mg/kg, 3 times daily for 40 days)
and cyclophosphamide (CPM) (40 mg/kg day 1, 60 mg/kg on days 8, 18, and 28) or CPM
monotherapy. Subjects were monitored for clinical and laboratory toxicity and had EBV levels
measured regularly. Dose-limiting toxicity (DLT) was our primary outcome.
Results—We found that the combination of valacyclovir and CPM was safe and did not lead to
any DLT compared with CPM monotherapy. The most common side effects were vomiting,
abdominal pain, and tumor site pain, which were similar in both arms. Patients with measurable
serum EBV showed decreased loads over their treatment course.
Conclusions—We recommend a phase II valacyclovir dose of 30 mg/kg 3 times daily for 40
days. We also observed that 6 of our 12 patients with presumed Burkitt lymphoma had measurable
EBV viral loads that decreased over the course of their treatment, suggesting that phase II studies
should investigate this correlation further. This study paves the way for a phase II efficacy trial of
combined valacyclovir and CPM in the treatment of endemic Burkitt lymphoma.
Introduction
Epstein-Barr virus (EBV) is a human herpesvirus that infects 90% of adults globally. EBV
can immortalize human B lymphocytes in cell culture and has been implicated in human
lymphomagenesis.1 Lymphoma subtypes having a strong association with EBV include
Burkitt lymphoma (BL), Hodgkin lymphoma (HL), B-cell lymphoproliferative disease in
immunosuppressed patients, and nasal NK-T–cell lymphoma. In areas endemic for BL, such
as Malawi and much of sub-Saharan Africa, virtually all tumors carry the virus, whereas
EBV is present in 15% to 20% of sporadic BL tumors occurring in high-income
countries.2–4 EBV infection is operative surgically in 90% of patients with
posttransplantation lymphoproliferative disease (PTLD), which occurs in up to 5% of organ
transplant recipients. Decreasing EBV-specific cytotoxic T lymphocytes and increasing
EBV viral load are strongly associated with PTLD development.5–7 EBV positivity is more
frequent in patients with HIV-associated non-Hodgkin lymphoma (NHL) than in NHL in
immunocompetent individuals, which is also likely a consequence of chronically impaired
cellular immunity.8 As effective antiretroviral therapy has led to marked reductions in HIV-
associated infectious complications, NHL has emerged as a principal cause of morbidity and
mortality among persons living with HIV in high-income countries.9–11 In patients with
HIV-associated NHL, EBV positivity has been demonstrated in 30% to 40% of HIV-
associated BL, 70% to 80% of HIV-associated diffuse large B-cell and plasmablastic
lymphoma, and virtually 100% of HIV-associated primary central nervous system (CNS)
lymphoma.12–14
It has been speculated that the addition of antiviral agents to chemotherapeutic agents in
EBV-related cancers would improve disease-free survival.15 Nucleoside analogue antiviral
agents such as valacyclovir are activated by EBV thymidine kinase (BXLF1) or serine/
threonine protein kinase/phosphotransferase (BGLF4), which are expressed only during the
lytic phase of EBV replication. In most EBV-related cancers, the virus exists in a latent form
and therefore does not express these kinases. However cells with latent EBV infection can
be induced to lytic infection with chemotherapy or radiation in vitro and in animal
models.16–20 Our proof of principle study of Malawian children with endemic BL found that
cyclophosphamide (CPM) induces EBV lytic-phase replication within 24 hours of initial
treatment.21
Nucleoside analogues have shown efficacy in managing active EBV infection,22 leading to
decreased oropharyngeal EBV titers among patients with infectious mononucleosis.23
Antiviral therapy directed against EBV has been principally studied in the context of PTLD
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and is generally ineffective (likely because the cells are latently infected), although there are
anecdotal reports of clinical response.24 More recently, a novel treatment strategy using
ganciclovir in combination with arginine butyrate—an amino acid derivative that induces
EBV thymidine kinase transcription and renders latently infected immortalized B
lymphocytes susceptible to ganciclovir—has shown some promise.25 As antiviral and
immunologic therapies directed against EBV continue to show promise in the context of
PTLD, these strategies may demonstrate applicability to other EBV-related
lymphoproliferative disorders.
Endemic BL in sub-Saharan Africa occurs in tropical malaria-prevalent areas. The median
age of onset is 8 years, and 60% to 70% of patients present with rapid tumor growth in the
mandible and/or maxilla, although abdominal, CNS, and other sites can also be involved.26
In high-income countries, treatment typically includes a combination of CPM, vincristine,
methotrexate, and additional agents, leading to survival rates >90%.27 Without adequate
resources for supportive care, similar multidrug regimens used in Malawi had only 33% 1-
year disease-free survival and unacceptably high levels of toxicity, with 14/42 (33%) cases
of mortality occurring during or directly after treatment (3 cases were attributed to disease
progression).28 In addition, chemotherapy agents are in limited supply. As a result, treatment
for BL at Kamuzu Central Hospital in Lilongwe, Malawi is generally CPM monotherapy,
given at 40 mg/kg once, followed by 60 mg/kg every 10 days for 3 more doses. Long-term
survival rates with this regimen are 48% (median follow up, 454 days).4
Although ganciclovir has thus far shown slightly greater efficacy against EBV-associated
disease such as PTLD,29 acyclovir has the advantages of being less toxic, less expensive,
and easier to dose,30–32 all of which are important factors in a resource-limited setting with a
proven history of inadequate supportive care.28 Valacyclovir is inexpensive and is approved
for use in the United States in children with herpes labialis (>12 years of age at 2 g every 12
hours for 1 day) and chickenpox (age >2 years, 20 mg/kg 3 times daily for 5 days).
Pharmacokinetic data in a study of children with EBV infection suggested that a
valacyclovir dose of 20 mg/kg is effective.33 The recommended prophylactic dose in
immunocompromised children is 30 mg/kg 3 times daily.34 Although valacyclovir
monotherapy has thus far proved safe, the safety of combined valacyclovir with CPM or
other chemotherapeutic agents in children with BL in sub-Saharan Africa has not been
assessed. These children are universally infected with malaria and are frequently
malnourished. Therefore phase I safety data are necessary to assess this combination and
dosing regimen before a phase II trial can be initiated.
The primary objectives of our study were to assess the toxicity of combined valacyclovir/
CPM and to determine a maximum tolerated dose (MTD) or a recommended phase II dose
for this regimen. Endemic BL provides a homogeneous population of EBV-associated
cancers to test the hypothesis that chemotherapy-induced lytic EBV infection will render




Children aged 3 to 15 years with expanding maxillary or mandibular masses, no previous
history of cancer treatment, and a Lansky performance score35 of 50 or greater were eligible
for the study. Although pathologic specimens were sent for histologic confirmation of BL,
treatment was initiated presumptively per standard of care, as pathologic confirmation can
take 6 to 8 weeks. Minimum laboratory requirements for study inclusion were a hemoglobin
level of 7 g/dL (after 10 mL/kg of whole blood transfusion if needed), white blood cell count
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of 2000 cells/µL, absolute neutrophil count (ANC) of 1000 cells/µL, and platelet count of
50,000 cells/µL. The maximum creatinine level allowed was 2.0 mg/dL. Subjects were
excluded for CNS symptoms (facial weakness, nonreactive pupil, marked visual changes),
known intolerance to study medications, or if they were receiving other investigational
drugs.
The study was approved by the University of North Carolina (UNC) Internal Review Board
(Study No. 10-0962) and the Malawi National Health Sciences Research Committee
(protocol 735). All guardians provided written informed consent before enrollment in the
study and age-appropriate children were asked to sign an assent.
Study Design
In this phase I open-label 3 + 3 dose-escalation study, we evaluated the safety and
tolerability of increasing doses of valacyclovir in combination with standard-dose CPM in
the treatment of BL in Malawi. Patients were enrolled at 15 mg/kg valacyclovir 3 times
daily for 40 days (day−2 to 38, level 1) and 30 mg/kg 3 times daily for 40 days (level 2); 15
mg/kg 3 times daily for 12 days (level −1) was planned but was not used. All patients
received CPM 40 mg/kg intravenously on day 1 and then 60 mg/kg on days 8, 18, and 28, as
is standard of care at Kamuzu Central Hospital, Lilongwe, Malawi. Study nurses provided
all doses of CPM and all doses of valacyclovir except in rare circumstances, ensuring
compliance. CPM dosing was delayed for hemoglobin levels <7 g/dL (after 10 mL/kg of
whole blood transfusion if needed), white blood cell count <2000 cells/µL, ANC <1000
cells/µL, platelet count < 50,000 cells/µL, and creatinine levels < 2.0 mg/dL, until those
values normalized. Dose-limiting toxicity (DLT) for combination valacyclovir and CPM
was defined as grade 3 or greater nonhematologic toxicity that was at least possibly
attributable to protocol therapy (except grade 3 nausea and vomiting that could be controlled
with antiemetic therapy and grade 3 infections), grade 4 hematologic toxicity lasting more
than 3 weeks, and grade 4 infections.36 Febrile neutropenia is common with CPM therapy
and has not been reported with valacyclovir. Therefore febrile neutropenia was not counted
as a DLT for this trial. Many patients receiving CPM are treated with intravenous
antibiotics, the definition of grade 3 infection, so this also was not counted as a DLT.
The dose-escalation plan was as follows: a 3-patient cohort was enrolled at dosage level 1,
(15 mg/kg/dose 3 times daily of valacyclovir from days −2 to 38) and was observed through
days 35 to 38 (7–10 days after the fourth dose of CPM). If no DLT was observed after all 3
subjects reached day 35, the dosing was escalated to 30 mg/kg/dose 3 times daily of
valacyclovir from days −2 to 38 (dose level 2) in another 3-patient cohort. If 1 DLT was
observed at dose level 1, 3 more subjects would enroll at dose level 1 and would be
observed through day 38 (10 days after the last dose of CPM). If 1 of 6 subjects had DLTs at
dose level 1, the study would escalate to dose level 2. If 2 or more DLTs were observed in 6
subjects at dose level 1, 3 subjects would enroll at dose level −1 (15 mg/kg/dose
valacyclovir 3 times daily on days −2 to 10). If there were no DLTs in these 3 subjects, dose
level −1 would be considered the MTD. If 1 DLT occurred in the first 3 subjects enrolled at
dose level −1, 3 more subjects would be enrolled. If 0/3 or one-sixth of the subjects
receiving dose level −1 had a DLT, this would be considered the MTD. If 2 or more DLTs
occurred in 6 subjects at dose level −1, the combination of valacyclovir and CPM would be
reviewed by both the Malawi and the UNC data safety monitoring committees to determine
if it was too toxic to consider a phase II trial.
If the study escalated to dose level 2, 3 subjects would be enrolled at this level and observed.
If no DLT was observed, 30 mg/kg/dose given 3 times daily would be considered the
recommended phase II dose, and a phase II study would be planned. If 1 DLT was observed
in the cohort of 3 subjects, 3 more subjects would be enrolled at dose level 2. If 1 or fewer
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DLTs were observed in 6 subjects at dose level 2, 30 mg/kg/dose given 3 times daily would
be considered the MTD. If 2 or more DLTs were observed at dose level 2, the MTD would
be exceeded, and dose level 1 would be considered the MTD.
Throughout the dose escalation, an equal number of control patients were enrolled in the
CPM arm. Toxicities were recorded for comparison in the same manner as the experimental
(combination CPM/valacyclovir) arm.
Assessments
Baseline data were collected before initiation of chemotherapy and included a complete
history, physical examination, tumor measurements, abdominal ultrasonogram, fine-needle
aspiration of tumor for histopathologic examination, and plasma EBV viral load
measurement. There is no scanning radiography at Kamuzu Central Hospital, so tumor
response was determined by clinically measuring tumor size with a tape measure in
horizontal, vertical, and longest dimensions. Plasma EBV levels were determined between
doses 3 and 4 of valacyclovir, within 6 hours of the first CPM dose, <48 hours before each
subsequent CPM dose, and 7 to 14 days after the final scheduled dose of CPM. A complete
history, physical examination including tumor measurements, and laboratory tests
(hemoglobin, hematocrit, white blood cell count with differential, platelets, creatinine, and
lactate dehydrogenase determinations) were performed <48 hours before each CPM dose, 7
to 14 days after the final scheduled dose of CPM, and as needed according to the Burkitt
ward clinician. The abdominal ultrasonogram was not repeated unless there was a recurrence
of disease.
Pathologic Examination
Kamuzu Central Hospital clinicians performed fine-needle aspiration by routine methods.
Samples were sent to the Imperial College London in London for analysis, and results were
not available before patients initiated treatment or during the trial.
EBV Viral Load
Blood was collected in a 5-mL ethylenediaminetetraacetic acid tube, and plasma separation
was performed within 4 hours. In the event of delay, the specimen was held at room
temperature for no more than 24 hours. Tubes were rotated gently 2 or 3 times and then
centrifuged at 500 g for 10 minutes. One-milliliter aliquots of plasma were removed and put
into 1.5-mL screw-top tubes and transferred to −80°C for storage and shipping on dry ice
from Malawi to UNC for testing.
Total nucleic acid was extracted from 200 µL of plasma using the High Pure Viral Nucleic
Acid Kit (Roche Diagnostics, Indianapolis, IN). Before extraction, 1 µL of TaqMan
exogenous internal positive control (Exo IPC [Applied Biosystems, Foster City, CA]) was
spiked directly into 200 µL of plasma to serve as an indicator of adequate DNA extraction
and amplification, and all specimens in this study were deemed adequate on interpretation of
the results. The final elution volume was 50 µL, and 5 µL was used for each polymerase
chain reaction (PCR). EBV BamH1W region PCR was run on ABI 7500 Real Time PCR
System (Applied Biosystems, Carlsbad, CA) in duplicate for each sample. EBV viral load
was calculated in EBV genome copies per milliliter plasma. Undetectable EBV DNA,
reported as a value of 1 for purposes of data analysis, indicates that results were smaller than
the limit of detection (250 copies per mL). Standards, primer sequences, and thermocycler
conditions were as previously described.37
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Sample size of the experimental arm was determined per 3 + 3 study design with an equal




Between January and June 2011, 13 patients were enrolled in the study, 3 at valacyclovir
dosage level 1 (15 mg/kg 3 times daily), 4 at dosage level 2 (30 mg/kg 3 times daily), and 6
as controls. One patient at dosage level 2 absconded after her second dose of CPM for social
reasons after near resolution of the tumor and was replaced.
Of the subjects completing treatment and the 1 who absconded, ages ranged from 3 to 15
years and there were 5 boys and 8 girls (Table 1). Children in the control group and
valacyclovir dosage level 1 group were stunted, with median height z scores of −3.28 and
−1.99, respectively. Reported duration of facial swelling on presentation ranged from 7 days
to 3 months. Abdominal masses confirmed by ultrasonography were found in 3 control
subjects, 2 subjects receiving valacyclovir dosage level 1, and all 3 subjects on valacyclovir
dosage level 2 (58% of all patients). All subjects had a Lansky performance score of 100.
Only 2 patients had biopsy-confirmed BL, including the patient who absconded, with the
remaining subjects having fine-needle aspirations with inadequate samples.
Safety
No DLTs or grade 3 or 4 adverse events attributable to the combination of valacyclovir and
CPM were observed. One patient experienced grade 3 anemia (hemoglobin level of 7.5 g/
dL) on study day 6. The patient had confirmed malaria based on a positive malaria parasite
smear with symptomatic recovery after 3 days of treatment, so this grade 3 toxicity was
attributed to malaria. Nearly all patients experienced grade 1 or 2 vomiting in the control
arm (5/6 patients), in the valacyclovir dosage level 1 (3/3 patients) arm, and in the dosage
level 2 (2/3 patients) arm (Table 2). All subjects had some degree of anemia. Estimated
creatinine clearance was similar between control (114.1 mL/min) and treatment (133.0 mL/
min) groups.
Essentially all patients experienced neutropenia, and 6 of 6 control and 3 of 6 experimental
arm patients experienced CPM treatment delays for neutropenia of 2 to 20 days. In eight-
ninths of these cases, the neutropenia occurred on day 16, between the second and third
doses of CPM. This is expected for patients treated with CPM and were not counted as
DLTs for the combination of valacyclovir and CPM.
No DLT attributable to the addition of 30 mg/kg/dose 3 times daily valacyclovir on days −2
to 38 to standard of care CPM was identified.
Efficacy
Of the 12 patients who completed therapy in all arms, 10 had a complete or nearly complete
response to treatment as measured by a change in tumor size at their day 35 to day 38
follow-up evaluation. For those patients with a partial response, we were unable to
determine whether a remaining mass was residual tumor or scar. One control patient and 1
patient receiving combined valacyclovir and CPM in the 30 mg/kg dose had progressive
disease at the end of treatment.
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Six of the 12 patients who finished treatment had a baseline detectable EBV viral load in
plasma. The 2 patients with progressive disease never had detectable circulating EBV DNA.
In all patients with an initial detectable EBV load, the viral load fell dramatically on
treatment with CPM, to nearly undetectable levels before the fourth dose (Figure 1). A
transient rise in plasma EBV viral load was seen in nearly all patients at various time points
during sequential monitoring of response to therapy, although by the end of therapy most
patients had achieved a 100- to 1000-fold reduction in EBV load. In this small study, there
was no discernible difference in serial viral loads between the 4 patients treated with CPM
and the 2 patients who received both CPM and valacyclovir.
Discussion
In this 3 + 3 phase I dose escalation study of endemic BL, the combination of valacyclovir
and CPM was safe in the study population and did not lead to any DLTs or serious adverse
events. The valacyclovir recommended phase II dose is 30 mg/kg 3 times daily for 40 days
with a CPM dose of 40 mg/kg on day 1, followed by 60 mg/kg on days 8, 18, and 28.
The most commonly reported adverse events in patients treated with and without
valacyclovir were vomiting, abdominal pain, and local pain at the tumor site, none of which
were grade 3 or greater. Adverse events occurred with equal frequency in both study arms,
and most symptoms reported are commonly associated with cyclophosphamide,38
suggesting that the addition of valacyclovir had a minimal impact on adverse events in this
cohort.
Although anemia was frequent in both study arms, the average hemoglobin concentration of
a healthy population of children in Malawi is 9.9 g/dL, and anemia secondary to malaria is
common.39 Malaria, with concurrent anemia, developed in 2 patients in the study during
treatment.
Six patients had a high plasma EBV viral load on diagnosis, and in all cases the viral load
remained elevated after the first dose of CPM but then decreased to nearly undetectable
levels over time. For the 2 patients receiving valacyclovir, there did not appear to be a
significant change in viral load during the 2-day period between when valacyclovir was
initiated and just before CPM was initiated, suggesting that the nucleoside analogue alone
has little impact on circulating EBV DNA levels. However CPM treatment clearly had an
effect on viral load. Six hours after the first dose of CPM, 2 of 5 evaluable patients had
increases in viral load. Our observation of transient elevation of viral load is consistent with
the findings in our proof of principle study, which also demonstrated an initial rise in EBV
viral load in about half of patients with BL treated with CPM.21 A transient rise in EBV
viral load has also been reported in EBV-infected nasopharyngeal carcinoma in which
researchers found that although EBV viral load becomes undetectable within 2 hours of
surgical resection,40 radiotherapy may lead to a transient increased EBV viral load that is
thought to be associated with tumor lysis.41 Six patients had undetectable EBV at diagnosis.
It is possible that in this small sample, the EBV-negative subjects had tumors other than
EBV-infected BL, although this finding differs from our proof of concept study, which
showed that 25/33 children (76%) with expanding solid maxillary or mandibular masses
were confirmed as having EBV-positive BL.21 The exact role of EBV in cellular
transformation and tumorigenesis is still poorly understood.42 Although data are
significantly limited, loss of EBV positivity has been reported in relapse among patients
with HL, suggesting that EBV infection may not be necessary once transformation has
occurred.43 Improved biopsy procedures and a larger sample size in a phase II trial would
provide a better understanding of this discrepancy.
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In nasopharyngeal carcinoma, EBV load may serve as a marker of disease progression. The
continued presence of circulating EBV 6 to 8 weeks after initiation of treatment was
predictive of residual disease, whereas undetectable EBV was associated with stable
remission.41,44,45 Serial testing was also shown to predict relapse before it became
symptomatic.45–47 To our knowledge, EBV load as a marker of disease burden has not been
established in EBV-related BL. For those patients in our study with a partial tumor response,
the histopathologic type of the residual mass was unknown, and we followed patients up to
38 days only, not a full year. However in our experience, many patients have a clinical
partial response as the tumor is replaced by scar, but they maintain a long disease-free
interval. Given these clinical characteristics, future studies should investigate the role of
circulating EBV loads and follow them for a longer period to learn the kinetics of EBV viral
load and its ability to predict tumor remission vs. relapse.
The lack of adequate biopsy specimens was unexpected in the study but does not affect the
conclusion that the combination of valacyclovir and CPM is safe in this patient population.
Patients presenting with suspected BL from January 2011 to August 2011 who were not
enrolled in the study also had an unexpectedly high rate of inadequate samples: 31% were
inadequate, 33% were blood only, and only 31% were BL. The cause for an increased rate of
assay failure compared with previous years is unclear because there was no obvious change
in the method of collection, preparation, or shipment of these samples, which have been
analyzed in this fashion for many years. In our previous proof of principle study, specimens
from fine-needle aspiration performed by the same Kamuzu Central Hospital clinician were
sent to the UNC and 25/33 children with expanding solid maxillary or mandibular masses
were confirmed as having EBV-positive BL as determined by UNC pathologists.21 Three
children had blood only in the specimen (likely geographic miss of lymphoma), 3 children
had other pathologic processes (1 each diffuse large cell lymphoma, granuloma, and reactive
node), and 2 specimens were inconclusive. After the last patient was enrolled in the current
study in July 2011, a pathology laboratory was opened at Kamuzu Central Hospital in
Malawi in collaboration with the UNC Project. Fine needle aspiration specimens are now
processed promptly and interpreted within 2 weeks. This should facilitate diagnosis and
timely tailored action by clinicians based on clinical findings combined with histopathologic
classification of the lesion. Another limitation of our study is that subjects in the control arm
had lower height-for-age z scores than did the subjects in the experimental arm. Malnutrition
and height stunting are common among children with cancer in the developing world,48
especially in Malawi,49 and have been shown to correlate with worse outcomes, including
overall decreased response to treatment50 as well as increased episodes of profound
neutropenia in patients with BL.51
Our data show that the addition of valacyclovir to standard of care CPM treatment for
endemic BL did not increase the risk of grade 3 or 4 adverse events. Subjects continued to
show a range of responses to treatment, but this phase I trial was not designed or powered to
examine efficacy. A phase II trial is planned to investigate efficacy and to further define the
side effect profile of combination valacyclovir and CPM in the treatment of endemic BL.
Although BL is relatively rare in developed countries, the study of endemic BL provides a
homogeneous population of EBV-associated cancer to test the hypothesis that
chemotherapy-induced lytic EBV infection will render EBV-associated cancer cells
susceptible to increased cell death by an antiviral nucleoside analogue.
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• There is interest in using nucleoside analogs against several Epstein-Barr virus
(EBV)-associated diseases including endemic Burkitt’s lymphoma (BL).
• Safety of nucleoside analogs in combination with chemotherapy in the
developing world has not been studied.
• We conducted a phase 1 3+3 dose-escalation trial and found that the
combination of valacyclovir (15 mg/kg and 30 mg/kg, 3 times daily for 40 days)
and cyclophosphamide (40 mg/kg day 1, 60 mg/kg on days 8, 18, and 28) was
safe and did not lead to any dose-limiting toxicity.
• The most common side effects observed were vomiting, abdominal pain, and
tumor site pain.
• We recommend a phase 2 valacyclovir dose of 30 mg/kg 3 times daily for 40
days.
• We also observed that 6 of 12 patients with presumed BL had measurable EBV
viral loads that decreased over the course of their treatment, suggesting phase II
studies should investigate this correlation further.
Olson et al. Page 12














Epstein-Barr Virus (EBV) Viral Load by Subject Number and Study Arm in Serial Plasma
Specimens. Dotted Lines Represents Valacyclovir-Cyclophosphamide Regimen, Solid Lines
Represent Cyclophosphamide Only
Abbreviations: Val = valacyclovir; CPM = cyclophosphamide.
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Table 1




15 mg/kg (n = 3)
Valacyclovir Group
30 mg/kg (n = 3)
Male Sex (%) 2 (33%) 1 (33%) 2 (67%)
Age, y (Median, Range) 7.5 (5–13) 10 (7–15) 6 (3–9)
Height/Age z-Score (Median) −3.28 −1.99 0.48
Duration of Facial Mass, d (Median, Range) 40.5 (20–90) 28 (21–30) 51 (7–51)
Facial Tumor Largest Diameter, cm (Median, Range) 5 (2.5–8) 9 (7–12) 7.5 (6–13)
Abdominal Mass Present, n (%) 3 (50%) 2 (67%) 2 (67%)
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